AZD6234
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
AstraZeneca · Phase 2 · Active, not recruiting · Enrollment 16
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| AZD6234 (sub-study 1) | Obesity or overweight | n/r | 16 | n/r | n/r |
| Placebo (sub-study 1) | Obesity or overweight | n/r | 16 | n/r | n/r |
| AZD9550(sub-study 2 Cohort A) | Obesity or overweight | n/r | 16 | n/r | n/r |
| Placebo (sub-study 2 Cohort A) | Obesity or overweight | n/r | 16 | n/r | n/r |
| AZD6234 in combination with AZD9550 (sub-study 2 Cohort B) | Obesity or overweight | n/r | 16 | n/r | n/r |
| Placebo (sub-study 2 Cohort B) | Obesity or overweight | n/r | 16 | n/r | n/r |